Ras Signaling in Cancer Nanocourse
Wednesday, November 13, 2013 at 1:00pm to 4:00pm
Goldenson Building, 122 220 longwood avenue
Nanocourse Faculty: Karen Cichowski, Kevin Haigis, William Hahn
At least 15% of all human cancers possess mutations in Ras oncogenes; however, mutations in upstream regulators and downstream effectors are also prevalent. In total, the Ras pathway is deregulated in the majority of human cancers. Nevertheless, while Ras has been extensively studied for 30 years, it is still unknown how this pathway drives human cancer. In this nanocourse, we will compare and contrast Ras signaling and its regulation in both normal and cancer cells with an emphasis on recent novel discoveries. Current and future therapeutics that target Ras or Ras-dependent pathways will also be discussed.
No recent activity